CVSA vs PRDO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PRDO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVSA and PRDO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVSA and PRDO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Covista Inc. is the largest healthcare educator in the United States by enrollment, running five accredited institutions across three reporting segments. Chamberlain University is the nursing school and the biggest single revenue line. Walden University is the online graduate institution, weighted toward master's and doctoral programs in nursing, health, education and social work. The Medical and Veterinary segment holds American University of the Caribbean School of Medicine, Ross University School of Medicine and Ross University School of Veterinary Medicine, with campuses in Barbados, St. Kitts and St. Maarten. Revenue is tuition, and a large share of that tuition is funded by federal Title IV student aid. The company is the former DeVry Education Group, which took the Adtalem name in 2017, sold DeVry University in 2018, and spent the four years after that reshaping around healthcare. It announced the Covista name on 5 February 2026 and the ticker moved from ATGE to CVSA on the NYSE on 24 February 2026.

Full CVSA guide

Perdoceo Education Corporation (Nasdaq: PRDO) is the Schaumburg, Illinois company that used to trade as Career Education Corporation; it took the Perdoceo name in December 2019 after shedding its campus-heavy culinary and art-school businesses. What remains is three accredited postsecondary institutions. Colorado Technical University is the largest, at ~32,110 students as of June 30, 2026 and about 69% of total enrolment, with roughly 98% of those students fully online. The American InterContinental University System adds ~10,510 students, also almost entirely online. The third piece, the University of St. Augustine for Health Sciences, is the odd one out and the interesting one: a campus-based graduate school in physical therapy, occupational therapy, speech language therapy and nursing, ~4,210 students, growing at ~6% while the two online universities are flat. Total enrolment across all three was ~46,830, up just ~0.7% year over year.

Full PRDO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CVSA drivers: Nursing demand and the Chamberlain pipeline; Walden's online graduate scale.
• PRDO drivers: St. Augustine is the only segment actually growing; Earnings growth is being manufactured below the revenue line.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is federal policy rather than competition. For PRDO, the dominant risk is regulatory concentration rather than competition: approximately ~$615 million of Title IV cash receipts in 2025 against ~$846.1 million of revenue means a change in federal aid rules, eligibility, or appropriations flows almost directly into the P&L, and management lists a government shutdown or Department of Education restructuring among its own guidance assumptions.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVSA if you believe its drivers more; PRDO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVSA and PRDO guides.

CVSA. Shares trade near ~$130, up roughly ~13% over the past 52 weeks, for an enterprise value of ~$5.0 billion and an EV/EBITDA multiple around ~9x on a ~26% adjusted EBITDA margin. That is a discount to the ~20x trailing P/E implied by GAAP earnings because adjusted profit runs well ahead of reported profit, a gap worth checking in the filings. Fiscal Q4 and full-year 2026 results land on 6 August 2026, and the published average analyst price target sits near ~$156.

PRDO. The trailing multiple looks unusually low until the cash is stripped out, at which point the enterprise is valued near ~6.5x trailing operating income and closer to ~5.5x on the adjusted figure. That is the market applying a persistent discount to Title IV dependence and litigation overhang rather than mispricing the cash flow, and it has been roughly the same discount for several years. Worth checking against the filings: a meaningful slice of 2026 EPS growth came from a lower effective tax rate (~20.6% year to date versus ~24.9%) that the company's own full year assumption of ~23.5% does not extend.

Headline figures (approximate, August 2026): CVSA shows revenue (ttm) ~$1.91 billion, adjusted eps (fy2026 guidance) ~$7.95 to ~$8.15, adjusted operating margin (q3 fy2026) ~21.0%, market cap ~$4.4 billion; PRDO shows revenue (ttm) ~$859M, from ~$846.1M in FY2025 and ~$435.1M in the first half of 2026, net income / diluted eps (ttm) ~$177M and ~$2.75, versus ~$159.9M and ~$2.42 for FY2025, market cap and p/e ~$2.03B at ~$32.50 per share, about ~11.9x trailing earnings, cash and short-term investments ~$734.8M with no conventional debt, roughly ~36% of market cap.

CVSA and PRDO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVSA and PRDO exposure against your real portfolio. It is not an investment adviser.